New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocyt ...

This study provides useful insights into addressing the question of whether the prevalence of autoimmune disease could be driven by sex differences in the T cell receptor (TCR) repertoire, correlating ...

B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predominantly of ...

Parkinson's disease (PD) is an age-related, progressive, neurodegenerative condition, caused by loss of dopamine-producing neurons.

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...

A phase 1/2 clinical trial examining the CRISPR-engineered allogeneic chimeric antigen receptor (CAR)-T candidate AVC-203 (QUADvance) has been approved by the FDA and the European Medicines Agency ...

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over ...

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...

Roswell Park scientists show that IL-36γ–armored CAR T cells reprogram neutrophils to trigger powerful immune responses ...

Epstein-Barr virus (EBV) infected and reprogrammed autoreactive B cells in patients with systemic lupus erythematosus (SLE) to become activated antigen-presenting cells. EBV-infected B cells in ...